IL36RN

Across TCGA pan-cancer cohorts, IL36RN mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IL36RN data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IL36RN mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated IL36RN expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC and LSCC are the cancer types where IL36RN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	IV	0.903	0.588	.013	12	view →
LSCC	DFS	Median	II,III,IV	0.892	0.458	.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

IL36RN–HNSC (OS)

Open the HNSC breakdown →